Literature DB >> 25071078

Falling insulin requirements are associated with adverse obstetric outcomes in women with preexisting diabetes.

Suja Padmanabhan1, Mark McLean2, N Wah Cheung3.   

Abstract

OBJECTIVE: To investigate the clinical significance of falling insulin requirements in women with preexisting or overt diabetes in pregnancy. RESEARCH DESIGN AND METHODS: A retrospective review of 139 pregnancies was conducted in women, with preexisting diabetes, delivering between January 2010 and January 2013. Women with falling insulin requirements of 15% or more from the peak total daily dose in late pregnancy were considered case subjects (n = 35). The primary outcome consisted of a composite of clinical markers of placental dysfunction, including preeclampsia, small for gestational age (SGA, ≤5th percentile for gestational age), stillbirth (>20 weeks), and premature delivery (≤30 weeks).
RESULTS: A total of 25.2% of women had >15% fall in insulin requirements with nulliparity as the only predictor at baseline (odds ratio [OR] 2.5 [95% CI 1.1-5.7], P = 0.03). Falling insulin requirements were associated with an increased risk of preeclampsia (OR 3.5 [1.1-10.7], P < 0.05) and the composite of clinical markers of placental dysfunction (4.4 [1.73-11.26], P = 0.002). Although falling insulin requirements were associated with higher rates of SGA (3.4 [1.0-11.3], P = 0.048), they were not associated with other adverse neonatal outcomes. However, there was a higher incidence of neonatal intensive care unit admission (15.5 [3.1-77.6], P = 0.001) and earlier delivery in this group (median 37.7 weeks [IQR 34.3-38.4] vs. 38.3 weeks [37.4-38.9], P = 0.014).
CONCLUSIONS: Falling insulin requirements, in women with preexisting diabetes, are associated with an increased risk of complications related to placental dysfunction. Further prospective studies are needed to guide clinical management.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25071078     DOI: 10.2337/dc14-0506

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

Review 1.  Drugs to Control Diabetes During Pregnancy.

Authors:  Maisa N Feghali; Jason G Umans; Patrick M Catalano
Journal:  Clin Perinatol       Date:  2019-03-26       Impact factor: 3.430

Review 2.  Placental Lactogen as a Marker of Maternal Obesity, Diabetes, and Fetal Growth Abnormalities: Current Knowledge and Clinical Perspectives.

Authors:  Rafał Sibiak; Maurycy Jankowski; Paweł Gutaj; Paul Mozdziak; Bartosz Kempisty; Ewa Wender-Ożegowska
Journal:  J Clin Med       Date:  2020-04-16       Impact factor: 4.241

3.  Potentially modifiable risk factors of preterm delivery in women with type 1 and type 2 diabetes.

Authors:  Julie C Søholm; Marianne Vestgaard; Björg Ásbjörnsdóttir; Nicoline C Do; Berit W Pedersen; Lone Storgaard; Birgitte B Nielsen; Lene Ringholm; Peter Damm; Elisabeth R Mathiesen
Journal:  Diabetologia       Date:  2021-06-19       Impact factor: 10.122

4.  Pregnancy Complicated by Maternal MODY 3 and Paternal MODY 2 Diabetes and Subsequent Rapidly Falling Insulin Requirement.

Authors:  Anastasia Mikuscheva; Adel Mekhail; Benjamin J Wheeler
Journal:  Case Rep Obstet Gynecol       Date:  2018-09-26

5.  A Clinical Update on Gestational Diabetes Mellitus.

Authors:  Arianne Sweeting; Jencia Wong; Helen R Murphy; Glynis P Ross
Journal:  Endocr Rev       Date:  2022-09-26       Impact factor: 25.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.